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Commentary "If it ain't broke, don't fix it": a commentary on the 
positive-negative results of the ACCORD Lipid study
Alexander Tenenbaum*1,2,3 and Enrique Z Fisman2,3
Abstract
Even using intensive statin monotherapy, many patients fail to achieve all the desired lipid goals and remain at high 
residual risk of cardiovascular events. In view of the still unproven decisively intensive "statin as monotherapy" strategy 
and "residual risk" concept, it is logical to ask whether other strategies, particularly fibrate/statin combination therapy, 
could be more beneficial and safer. A clear benefit of fibrate monotherapy did emerge previously among patients with 
atherogenic dyslipidemia (particularly high triglycerides and low high density lipoprotein cholesterol [HDL-C]) typically 
present in the metabolic syndrome and type 2 diabetes. In contrast, in patients without atherogenic dyslipidemia this 
favorable effect was not demonstrated.
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study investigated whether combination therapy with 
a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients 
with type 2 diabetes mellitus. However, relevant patients with atherogenic dyslipidemia represented less than 17 
percent of the ACCORD Lipid population (941 out of 5518 patients). In this prespecified subgroup, the patients 
benefited from fenofibrate therapy in addition to simvastatin similar to the previous "fibrate's as monotherapy" trials: 
the primary outcome rate was 12.4% in the fenofibrate group, versus 17.3% in the placebo group (28% crude HR 
reduction, CI less than1, e.g. statistically significant findings). Among all other 4548 patients without atherogenic 
dyslipidemia such rates were 10.1% in both fenofibrate and placebo study groups. Authors concluded that in the 
overall cohort of patients the combination of fenofibrate and simvastatin did not reduce the rate of the cardiovascular 
events as compared with simvastatin alone. Thus, their results do not support the routine use of combination therapy 
with fenofibrate and simvastatin to reduce cardiovascular risk in the general patients with type 2 diabetes. A recent 
large meta-analysis regarding effects of fibrates on cardiovascular outcomes noted greater effect sizes in trials that 
recorded a higher mean baseline triglyceride concentration (p = 0.030). As expected, in a so called "general 
population", reflecting a blend of effects in patients with and without atherogenic dyslipidemia, a mean "diluted" effect 
of fibrate therapy was reduced, but still producing a significant 10% relative risk (RR) decrease in major cardiovascular 
events (p = 0.048) and a 13% RR reduction for coronary events (p < 0.0001).
It should be pinpointed that the epidemiological characteristics of the ACCORD Lipid study depart from those seen in 
real clinical practice: among people with type 2 diabetes, there is a high prevalence of atherogenic dyslipidemia and 
metabolic syndrome. For example, an analysis of NHANES III data in adults aged ≥50 years showed that approximately 
86% of patients with type 2 diabetes also had the metabolic syndrome. Therefore, an importand finding of ACCORD 
Lipid study was the observation that fibrates may lead to cardiovascular risk reduction in patients with atherogenic 
dyslipidemia not only as monotherapy but in combination with statins as well.
In conclusion, in patients with atherogenic dyslipidemia (high triglycerides and low HDL-C, fibrates -- either as 
monotherapy or combined with statins - were associated with reduced risk of cardiovascular events. In patients 
without dyslipidemia this favorable effect - as expected - was absent.
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Introduction
The ACCORD Lipid study: Brief formal overview
The Action to Control Cardiovascular Risk in Diabetes
(ACCORD) study investigated whether combination
therapy with a statin plus a fibrate, as compared with sta-
tin monotherapy, would reduce the risk of cardiovascular
disease in patients with type 2 diabetes mellitus who were
a t hi gh ris k  f or ca r di ovascular  disease  [1] .  In t his  t ria l
5518 patients with type 2 diabetes were randomly
assigned to receive simvastatin plus fenofibrate or sim-
vastatin alone (simvastatin plus placebo). The primary
outcome was the first occurrence of nonfatal myocardial
infarction, nonfatal stroke, or death from cardiovascular
causes. The mean follow-up was 4.7 years. The annual
rate of the primary outcome was 2.2% in the fenofibrate
group and 2.4% in the placebo group (hazard ratio in the
fenofibrate group, 0.92; 95% confidence interval [CI], 0.79
to 1.08; P = 0.32). There were also no significant differ-
ences between the two study groups with respect to any
secondary outcome. Annual rates of death were 1.5% in
the fenofibrate group and 1.6% in the placebo group (haz-
ard ratio, 0.91; 95% CI, 0.75 to 1.10; P = 0.33). Prespeci-
fied subgroup analysis suggested a possible interaction
according to lipid subgroup, with a possible benefit for
patients with both a high baseline triglyceride level and a
low baseline level of high-density lipoprotein cholesterol
(P = 0.057 for interaction). Authors concluded that in the
overall cohort of patients the combination of fenofibrate
and simvastatin did not reduce the rate of the cardiovas-
cular events as compared with simvastatin alone. Thus,
these results do not support the routine use of combina-
tion therapy with fenofibrate and simvastatin to reduce
cardiovascular risk in the the general patient with type 2
diabetes.
Despite the aforementioned conclusion, an in-depth
examination of the ACCORD study itself and of several
other mainstay trials concerning the pharmacological
management of dyslipidemia, yields a completely differ-
ent clinical picture. Namely, fibrates -- alone or combined
with statins -- emerge as a proficient therapeutic tool
leading to an improved cardiovascular outcome. This
appraisal is depicted in the present commentary.
Discussion
Deadlock of the "statins as monotherapy" strategy
Even using intensive statin monotherapy, many patients
with atherogenic dyslipidemia fail to achieve all the
desired lipid goals and remain at high residual risk of car-
diovascular events [2]. In addition, the prescription of
statins in high doses may have important limitations in
daily clinical practice: compared with low-dose therapy,
intensive statin therapy has been associated with
increased incidence of discontinuation, hepatotoxicity
and myalgia [3]. Moreover, the incidence of side effects
with intensive statin therapy in clinical practice might be
higher than the figures reported in clinical trials as a
result of the careful selection of patients (such as the
exclusion of patients with known previous intolerance to
statins). Observational studies suggest that muscle-
related symptoms can be frequent in patients on statins;
for example, they have been registered in 18.2% of
patients receiving simvastatin [4].
Direct testing of varying degrees of low density lipopro-
tein cholesterol (LDL-C) lowering by using of active com-
parators (statin vs. statin) has been tested in 4 large
outcomes trials[5-8]: PROVE IT--TIMI 22, A to Z, TNT
and IDEAL. The fifth and largest of the trials [9] compar-
ing intensive vs. standard-dose statins therapy, the Study
of the Effectiveness of Additional Reductions in Choles-
terol and Homocysteine (SEARCH), was expected to
report its final conclusions in 2008 [9], but mysteriously
disappeared from the scientific horizons (suggestively
due to negative results).
The 'scores' of these trials where 'positive' means 'in
favor of intensive LDL-C-lowering strategy using statins
as monotherapy' are as follows:
1. PROVE IT--TIMI 22: high-dose strong atorvastatin
(80 mg/day) demonstrated a modest 16% relative reduc-
tion in the risk of death and major cardiovascular events
vs. medium-dose gentle pravavastatin (80 mg/day), which
was observed over the subsequent 2 years following an
acute coronary syndrome. It is a "positive" result - in favor
of the concept of intensive statin therapy, but it was based
on very strange study design.
2. the A to Z trial compared early intensive (40 mg/day
of simvastatin for 1 month followed by 80 mg/day there-
after, n = 2,265) versus a delayed conservative strategy
(receiving placebo for 4 months followed by 20 mg/day of
simvastatin, n = 2,232) in patients with acute coronary
syndromes. It was a "negative" study which did not
achieve the prespecified end point.
3. The Treating to New Targets (TNT) trial: There were
reductions in cardiovascular death, myocardial infarction
(MI), need for revascularization, and stroke with use of
high-dose vs. standard-dose atorvastatin. Although the
trial results were consistent with the concept that for cho-
lesterol, "the lower the better", concerns were raised
regarding a nonsignificant difference in total and noncar-
diovascular death in favor of less intensive statins therapy.
In other words, the most important issue for both
patients and clinicians, a hard end-point -- total death --
moved in a wrong direction in this "positive" study.
4. The Incremental Decrease in End Points Through
Aggressive Lipid Lowering (IDEAL) trial. In this study of
patients with previous MI, intensive lowering of LDL-C
(80 mg/day; n 4,439) did not result in a significant reduc-
tion in the primary outcome of major coronary events vs.
usual-dose simvastatin (20 mg/day; n = 4,449). ThereTenenbaum and Fisman Cardiovascular Diabetology 2010, 9:24
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were no differences in cardiovascular or all-cause mortal-
ity. Patients in the atorvastatin group had higher rates of
drug discontinuation due to nonserious adverse events.
"Negative" results.
So, out of the 5 trials which investigated intensive vs.
standard statin regime, we have 2 "positive" with reserva-
tions (PROVE IT--TIMI 22 and TNT), 2 "negative" (A to
Z and IDEAL) and 1 "missed" (SEARCH - suggestively
negative). Alas, until now the bitterest comparator for the
"intensive" statin monotherapy was 'usual-dose" statin
monotherapy... then, in view of the lack of a proven effect
of the current intensive "statin as monotherapy" strategy
and "residual risk" concept, it is logical to ask whether
other strategies could be more beneficial and safer [10].
Fibrates: Evidences before the ACCORD Lipid study
Fibrates have been used in clinical practice for more than
four decades due to their ability to substantially decrease
triglyceride levels, increase HDL-C levels and in addition
moderately but significantly reduce LDL-C [10]. Due to
their beneficial effects on glucose and lipid metabolism,
peroxisome proliferators-activated receptors (PPARs)-
alpha agonists (fibrates) are good potential candidates for
reducing the cardiovascular risk in subjects with athero-
genic dyslipidemia typically present in the metabolic syn-
drome and type 2 diabetes [11-13].
Although less clinical intervention studies have been
performed with fibrates than with statins, there were
clear evidences that two of the fibric acid derivates --
gemfibrozil and bezafibrate -- reduce the risk of cardio-
vascular disease [14-20]. Interestingly, reduction of car-
diovascular disease was more pronounced in patients
displaying baseline characteristics very similar to meta-
bolic syndrome definitions [14,15,21].
The primary-prevention trial Helsinki Heart Study
(HHS) showed that treatment with gemfibrozil led to a
significant reduction in major cardiovascular events [14].
In the Secondary prevention Veterans Affairs High-den-
sity lipoprotein cholesterol Intervention Trial (the
VAHIT study) - which included 30% of diabetic patients -
- gemfibrozil reduced the occurrence of major cardiovas-
cular events by 22% [15]. Again, reduction of cardiovas-
cular disease with gemfibrozil was more pronounced in
patients displaying more than three of the features of
metabolic syndrome [22,23]. The 18-year results from the
Helsinki Heart Study shows that patients in the original
gemfibrozil group had a 23% lower risk of CHD mortality
compared with the original placebo group. Interestingly,
those in the highest tertile of both body mass index and
triglyceride level at baseline had the most dramatic risk
reductions with gemfibrozil -- 71% (!) for coronary heart
disease (CHD) mortality and 33% for all-cause mortality
[24].
In the Bezafibrate Infarction Prevention (BIP) study an
overall trend of a 9.4% reduction of the incidence of pri-
mary end point (fatal or nonfatal myocardial infarction or
sudden death) was observed. The reduction in the pri-
mary end point in 459 patients with high baseline triglyc-
erides (above 200 mg/dl) was significant [19]. Recent
extension of the BIP trial demonstrated that patients with
metabolic syndrome might be the ones to obtain the most
marked benefit from therapy with fibrates [21,25-29].
Overall, bezafibrate treatment was associated with a
reduced risk for fatal and nonfatal MI with hazard ratio
(HR) and confidence interval (CI) of 0.71 (0.54-0.95) and
0.67 (0.49-0.91), respectively. The cardiac mortality risk
tended to be lower on bezafibrate (HR 0.74, CI 0.54-1.03).
Similarly to gemfibrozil Helsinki Heart Study extension,
in patients with augmented features of metabolic syn-
drome [21] (at least 4 risk factors for metabolic syn-
drome) a marked (56%!) reduction in cardiac mortality
was observed (HR 0.44, CI 0.25-0.80). In contrast, in
patients without atherogenic dyslipidemia this favorable
effect was absent: there was no significant difference in
the cardiovascular end points between bezafibrate and
placebo groups (for example, cardiac death was 7.7% vs.
7.7%). Also for fenofibrate, a post hoc analysis of the
FIELD study suggested a benefit for patients with both
elevated triglyceride levels and low HDL cholesterol lev-
els [30]. A recent large meta-analysis [31] regarding the
effects of fibrates on cardiovascular outcomes noted
greater effect sizes in trials that recorded a higher mean
baseline triglyceride concentration (p = 0.030). As
expected, in a so called "general population" -- reflecting a
blend of effects in patients with and without atherogenic
dyslipidemia - a "mean diluted" effect of fibrate therapy
was reduced, but still produceing a significant 10% rela-
tive risk (RR) decrease in major cardiovascular events (p
= 0.048) and a 13% RR reduction for coronary events (p <
0.0001).
Therefore, a clear benefit of fibrate therapy did emerge
among patients with atherogenic dyslipidemia (particu-
larly high triglycerides and low HDL-C). This is the sub-
group of patients for which fibrate treatment is indicated
under current guidelines (exepting bezafibrate, which has
been also used to treat biliary damage), this is the sub-
group of patients in whom fibrates are typically pre-
scribed in clinical practice and this is the subgroup of
patients which should be investigated in the large clinical
trial. So, it remains embarrassing that after all the
achievements, mistakes and lessons of the previous
fibrate's studies, an appropriate trial design has still not
been utilized for fenofibrate.
The ACCORD Lipid study: fibrate/statin combination in 
patients with atherogenic dyslipidemia
The researchers who planed the ACCORD Lipid study
faced a conundrum when starting the trial [32], question-
ing whether it would be best to test the addition of fenofi-
brate to statin therapy in patients with dyslipidemia, inTenenbaum and Fisman Cardiovascular Diabetology 2010, 9:24
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those with low HDL- C and high triglyceride levels (an
appropriate population), or in a broader spectrum of
patients (an inappropriate but larger population). Choos-
ing the latter, they at least prespecified a number of
subgroups, including patients with dyslipidemia. Unfor-
tunately, patients with atherogenic dyslipidemia for
whom fibrate is indicated represented less than 17 per-
cent of the ACCORD Lipid population (941 out of 5518
patients), whereas in routine clinical practice the size of
the problem is significantly greater. Anyway, in this sub-
group analysis, the patients with higher baseline triglyc-
erides and lower HDL-C levels benefited from fenofibrate
therapy in addition to simvastatin, similarly to the previ-
ous fibrate's as monotherapy trials: the primary outcome
rate was 12.4% in the fenofibrate group, versus 17.3% in
the placebo group (28% crude HR reduction, CI less than
1, e.g. statistically significant findings). Among all other
4548 patients included in this analysis (patients without
atherogenic dyslipidemia) such rates were 10.1% in both
fenofibrate and placebo study groups.
Obviously, the epidemiological characteristics of
ACCORD Lipid study depart from the real clinical prac-
tice: among people with type 2 diabetes, there is a high
prevalence of atherogenic dyslipidemia and metabolic
syndrome [33,34], which further accentuates cardiovas-
cular risk. For example, an analysis of NHANES III data
in adults aged ≥50 years showed that approximately 86%
of patients with diabetes had also metabolic syndrome
[33]. In this report, the prevalence of CHD was higher in
those people with both diabetes and metabolic syndrome
compared with those with diabetes alone (19.2% vs 7.5%).
It was probably hard, but the researchers who planned
ACCORD Lipid study succeeded to recruit a vast major-
ity of patients with lipid profile uncommon in type 2 dia-
betes. Anyway, pooled together, evidence consistently
demonstrated that fibrates offer optimum cardiovascular
benefit in patients with atherogenic dyslipidemia. This
dyslipidemia is typical for the metabolic syndrome and
for most (but not all, as was confirmed by the ACCORD
Lipid study researchers) patients with type 2 diabetes. In
our point of view, the main finding of ACCORD Lipid
study was the observation that fibrates may lead to car-
diovascular risk reduction in patients with atherogenic
dyslipidemia not only as monotherapy but in combina-
tion with statins as well.
Conclusions
In patients with atherogenic dyslipidemia (high triglycer-
ides and low HDL-cholesterol) fibrates both as mono-
therapy and as combination with statins were associated
with reduced risk of cardiovascular events. In patients
without dyslipidemia this favorable effect was absent:
don't prescribe fibrates for these patients, please.
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